Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6687688 | 0.99 | L3MBTL1 (0.43) | L3MBTL1ENPP2SIGMAR1HTR2CSLC6A4 | |
| SCHEMBL6680503 | 0.97 | ENPP2 (0.45) | L3MBTL1ENPP2SIGMAR1HTR2CSLC6A4 | |
| SCHEMBL6681828 | 0.95 | ENPP2 (0.43) | L3MBTL1ENPP2SIGMAR1HTR2CSLC6A4 | |
| SCHEMBL6675898 | 0.91 | ALDH1A1 (0.43) | L3MBTL1ENPP2HTR2CSLC6A4HSD11B1 | |
| SCHEMBL18154489 | 0.89 | L3MBTL1 (0.41) | L3MBTL1SIGMAR1HSD11B1ALDH1A1MAPK1 | |
| SCHEMBL5727402 | 0.89 | CCR5 (0.41) | L3MBTL1SLC6A4HSD11B1CCR5 | |
| SCHEMBL18163696 | 0.88 | CCR5 (0.47) | L3MBTL1SIGMAR1HSD11B1CCR5 | |
| SCHEMBL18154352 | 0.87 | HSD11B1 (0.48) | HSD11B1CCR5 | |
| SCHEMBL18154101 | 0.86 | KLK7 (0.42) | L3MBTL1HSD11B1ALDH1A1MAPK1CTSL | |
| SCHEMBL5725684 | 0.86 | OPRM1 (0.51) | SIGMAR1HTR2CHSD11B1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| CN-1150206-C | Bradykinin antagonist peptides containing N-substituted glycines | — | 2004-05-19 | — | — | CN | disclosed |
| US-5700779-A | ALLEVIATING PAIN, ASTHMA, INFLAMMATION, CEREBRAL EDEMA, CARDIOVASCULAR DYSFUNCTION | CORTECH, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| CN-1148393-A | Bradykinin antagonist peptides incorporating N-substituted glycines | CORTECH INC (US) | 1997-04-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | L3MBTL1 338/4885ENPP2 4486/4885SIGMAR1 68/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | L3MBTL1 743/4885ENPP2 2906/4885SIGMAR1 331/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | L3MBTL1 342/4885ENPP2 4508/4885SIGMAR1 71/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | L3MBTL1 831/4885ENPP2 2898/4885SIGMAR1 489/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | L3MBTL1 743/4885ENPP2 2906/4885SIGMAR1 331/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | L3MBTL1 449/4885ENPP2 3192/4885SIGMAR1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.